High-Dose Sertraline Strategy for Nonresponders to Acute Treatment for Obsessive-Compulsive Disorder: A Multicenter Double-Blind Trial
The DOI matches its Crossref record.
Abstract
OBJECTIVE: To evaluate the efficacy and safety of high-dose sertraline for patients with obsessive-compulsive disorder (OCD) who failed to respond to standard sertraline acute treatment. METHOD: Sixty-six nonresponders to 16 weeks of sertraline treatment who met DSM-III-R criteria for current OCD were randomly assigned, in a double-blind continuation phase of a multicenter trial, either to continue on 200 mg/day of sertraline or to increase their dose to between 250 and 400 mg/day for 12 additional weeks. Efficacy measures included the Yale-Brown Obsessive Compulsive Scale (YBOCS), the National Institute of Mental Health Global Obsessive Compulsive Scale (NIMH Global OC Scale), and the Clinical Global Impressions-Severity of Illness and -Improvement (CGI-I) scales. Data were collected from July 26, 1994, to October 26, 1995. RESULTS: The high-dose (250-400 mg/day, mean final dose = 357, SD = 60, N = 30) group showed significantly greater symptom improvement than the 200-mg/day group (N = 36) as measured by the YBOCS (p = .033), NIMH Global OC Scale (p = .003), and CGI-I (p = .011). Responder rates (decrease in YBOCS score of > or = 25% and a CGI-I rating < or = 3) were not significantly different for the 200-mg/day versus the high-dose sertraline group, either on completer analysis, 34% versus 52%, or on endpoint analysis, 33% versus 40%. Both treatments showed similar adverse event rates. CONCLUSION: Greater symptom improvement was seen in the high-dose sertraline group compared to the 200-mg/day dose group during continuation treatment. Both dosages yielded similar safety profiles. Administration of higher than labeled doses of selective serotonin reuptake inhibitors may be a treatment option for certain OCD patients who fail to respond to standard acute treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Sertraline [659,710,711,713,714,723-725] 1 IV clomipramine [742-744] 2”
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Self-citationStein, D. J., Costa, D. L. C., Lochner, C., Miguel, E. C., Reddy, Y. C. J., Shavitt, R. G., van den Heuvel, O. A., & Simpson, H. B. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0102-3 · Cited by 895
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“Increasing the dose of an SSRI, sometimes beyond formulary limits, may be beneficial (Ninan et al., 2006; Pampaloni et al., 2010).”
BackgroundJacobson, N. C., & Newman, M. G. (2017) · Psychological Bulletin · doi:10.1037/bul0000111 · Cited by 576
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Meta-analysis of the dose-response relationship of SSRI in obsessive–compulsive disorder
Bloch, M. H., McGuire, J., Landeros-Weisenberger, A., Leckman, J. F., & Pittenger, C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.50 · Cited by 317
Hudak, R., & Gannon, J. M. (2022) · Current Clinical Practice · doi:10.1007/978-3-030-98709-1_5 · Cited by 306
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297
Pharmacotherapy of Obsessive-compulsive Disorder and Obsessive-Compulsive Spectrum Disorders
Denys, D. (2006) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2006.02.013 · Cited by 213
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211
Fineberg, N. A., Reghunandanan, S., Simpson, H. B., Phillips, K. A., Richter, M. A., Matthews, K., Stein, D. J., Sareen, J., Brown, A., & Sookman, D. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.12.003 · Cited by 150
Unmet need for services and interventions among adolescents with mental disorders
Wang, P. S., Sherrill, J., & Vitiello, B. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.1.1 · Cited by 123
Pharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412461958 · Cited by 122
“Ninan et al. (2006) evaluated the efficacy and safety of high-dose (400 mg) sertraline in OCD patients who had failed to respond to 16 weeks of standard dose (200 mg) sertraline.”
BackgroundSerotoninergic mechanisms in the treatment of obsessive–compulsive disorder
Goddard, A. W., Shekhar, A., Whiteman, A. F., & McDougle, C. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.12.009 · Cited by 112
Sousa, M. B., Isolan, L. R., Oliveira, R. R., Manfro, G. G., & Cordioli, A. V. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0717 · Cited by 110
“However, it is possible that, with a higher dose, some patients may have a different outcome.(40) The inclusion of patients who had undergone previous treatment with a SRI could be a limitation of this study, as a lack of response to prior adequate trials of an appropriate SSRI would lead one to predict less likelihoo…”
BackgroundDiagnosis and treatment of postpartum obsessions and compulsions that involve infant harm
Hudak, R., & Wisner, K. L. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11050667 · Cited by 95
“Of the classes of antidepressants available for use in major depression, only selective serotonin reuptake inhibitors and clomipramine, a tricyclic antidepressant, are recommended for first-line use in OCD, and at higher dosages than are commonly used for depression (12).”
BackgroundFormulation and pharmacology of long-acting rilpivirine
Williams, P. E., Crauwels, H. M., & Basstanie, E. D. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000164 · Cited by 86
Bandelow, B., Allgulander, C., Baldwin, D. S., Costa, D. L. D. C., Denys, D., Dilbaz, N., Domschke, K., Hollander, E., Kasper, S., Möller, H.-J., et al. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2086296 · Cited by 84
“In a double-blind study comparing sertraline 200mg/day with higher doses (250–400mg/day) in nonresponders, greater symptom improvement was seen in the high-dose group (Ninan et al. 2006).”
BackgroundA randomized controlled trial of medication and cognitive-behavioral therapy for hypochondriasis
Fallon, B. A., Ahern, D. K., Pavlicova, M., Slavov, I., Skritskya, N., & Barsky, A. J. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16020189 · Cited by 65
“Higher dosing has been associated with greater improvement in trials of obsessive-compulsive disorder and depression (40, 41) and was associated with more substantial improvement in this study.”
A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder
Stein, D. J., Koen, N., Fineberg, N., Fontenelle, L. F., Matsunaga, H., Osser, D., & Simpson, H. B. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0268-9 · Cited by 65
Van Ameringen, M., Simpson, W., Patterson, B., Dell’Osso, B., Fineberg, N., Hollander, E., Hranov, L., Hranov, G., Lochner, C., Karamustafalioglu, O., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113517955 · Cited by 65
Barton, S., Karner, C., Salih, F., Baldwin, D. S., & Edwards, S. J. (2014) · Health Technology Assessment · doi:10.3310/hta18500 · Cited by 36
Obsessive-compulsive disorder – A state-of-the-art review
Endres, D., Schiele, M. A., von Zedtwitz, K., Dressle, R. J., Maier, A., Hohagen, F., Baldermann, J. C., Coenen, V. A., Jelinek, L., Domschke, K., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106320 · Cited by 11
Metadata
- Authors
- Ninan, P. T., Koran, L. M., Kiev, A., Davidson, J. R. T., Rasmussen, S. A., Zajecka, J. M., Robinson, D. G., Crits-Christoph, P., Mandel, F. S., & Austin, C.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2006-01-15
- Volume
- 67
- Issue
- 01
- Pages
- 15-22
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1969815463
- Cited by
- 245
- References
- 0
- FWCI
- 18.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.